With respect to the 2026 RSU grants to U.S. employees, RSUs vest annually in equal tranches over three years, from April 19, 2026 to April 19, 2029. Each vested RSU entitles the holder to receive one ...

X-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in monthly seizure frequency in 25 mg group vs. 10.4% for placebo and increasing rates of 100% seizure reduction over time ...

OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as those with best response of progressive disease This is the ...

Patients with RAS G12D non-small cell lung cancer remain a population with a significant unmet medical need for targeted therapeutic options,” said Jonathan Riess M.D., medical director of thoracic ...

Fedora Pharmaceuticals, Inc., a leader in the development of drugs to treat antibiotic-resistant infections, is presenting a full suite of preclinical findings from the company’s lead candidate, ...

The Herz P1 is positioned as a standalone fingertip pulse oximeter built for daily home monitoring. The company's marketing focuses on adults managing COPD, heart conditions, post-surgery recovery, ...

Vigor Boost is presented as a dietary supplement sold in gummy form, described as a male vitality support formula. According to the company's website, the product is designed to support men's virility ...

Ismail L. Ali, J.D., Co-Executive Director, MAPS As federal agencies are directed to reduce barriers to clinical research and accelerate drug approvals for psychedelic substances, it is critical that ...

PLN-101095 was generally well tolerated across all doses evaluated with few discontinuations (n=2) due to adverse events. Rash was the most common treatment-related adverse event (TRAE), all Grade 1 ...

ADAPT SERON, OCULUS, and Jr study results build on VYVGART's approved gMG indication and show its potential as the first and only biologic therapy effective across MG subtypes ADHERE post hoc analysis ...

ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study. First head-to-head, double-blind, randomized phase 4 study powered to ...

References to benefits, side effects risk, and customer complaints reflect commonly searched consumer questions and are included to address public interest topics in a clear, informational manner.